UK Biotech Booms But Will It Ever Produce A Big Player?

Investment From US On The Rise

Any chance that Kymab would advance to become a fully integrated biopharma has gone with Sanofi's deep pockets turning the heads of investors. Is the UK ever likely to develop its own Amgen or Moderna?

piggby bank
Temptation to cash in early proves too much for UK biotechs • Source: Shutterstock

News that Kymab Ltd is to be acquired by Sanofi has led some to lament the sale of yet another UK firm, once again raising concerns about the country's ability to build sustainable biotech businesses.

Cambridge-based monoclonal antibody expert Kymab is going to become part of the French giant after Sanofi agreed a $1.1bn upfront...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip